Q1 EPS Forecast for Sage Therapeutics Boosted by Analyst
Equities research analysts at HC Wainwright raised their Q1 2025 earnings per share estimates for Sage Therapeutics in a ...
manilatimes7h
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Guggenheim Securities, LLC acted as book-running manager for the offering. H.C. Wainwright & Co. and Lucid Capital Markets, ...
Quantum BioPharma Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from ...
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...
TELO Again Announces Breakthrough Results
TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...
GVB Biopharma Launches State-of-the-Art Isolation Facility with Over 300,000-Kilo Annual Production Capacity
GVB Biopharma, the largest global producer of cannabinoids, is proud to announce the launch of its cutting-edge isolation facility, marking a significant leap in production capabilities and efficiency ...
Valeo Financial Advisors LLC Acquires 3,309 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)
Valeo Financial Advisors LLC lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 32.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The ...
manilatimes16h
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
Olema Pharmaceuticals, Inc. ("Olema” or "Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...
Chimerix Shares Touch 52-Week High on Speedy FDA Review of Brain Tumor Treatment
Shares of Chimerix hit a new 52-week high Tuesday after the biopharmaceutical company said the Food and Drug Administration granted a priority review for its proposed dordaviprone treatment for a ...
Halozyme Therapeutics: Q4 Earnings Snapshot
Halozyme Therapeutics expects full-year earnings in the range of $4.95 to $5.35 per share, with revenue in the range of $1.15 billion to $1.23 billion. This story was generated by Automated Insights ( ...
How Biotech Can Succeed Outside the Hubs
Though most biopharma investment is in two states, follow this model to bring the research—and investments—elsewhere.
Positive Long-Term Outlook for Narrow-Moat Siegfried as Drug Outsourcing Demand Remains Strong
We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...